Kojima R, Ito M, Suzuki Y
Jpn J Pharmacol. 1987 Jan;43(1):73-80. doi: 10.1254/jjp.43.73.
Effects of tobramycin (TOB) alone and in combination with latamoxef (LMOX) on the stability of rat kidney lysosomal membranes were investigated. Rats were injected with doses of TOB (90 mg/kg/day, s.c.) alone. LMOX (2,000 mg/kg/day, s.c.) alone or TOB (90 mg/kg/day, s.c.) and LMOX (2,000 mg/kg/day, s.c.) for 5 consecutive days. The rat kidney lysosomes were isolated on the 1st, 3rd and 5th days and incubated in a 0.25 M sucrose solution containing 1 mM EDTA (pH 7.0) at 37 degrees C for 20 min. After incubation, the activity of N-acetyl-beta-D-glucosaminidase (NAG) released from lysosomes was measured, and the percent NAG release was calculated as an index of the stability of lysosomal membranes. The percent releases of NAG from lysosomes of TOB alone-treated rats were 40 and 50% greater than those of normal rats on the 1st and 3rd days, respectively. On the other hand, treatment with TOB and LMOX suppressed the NAG release from lysosomes with TOB alone by about 80 to 100%. There were insignificant slight increases in the percent NAG release in LMOX alone-treated rats on the 3rd and 5th days. In addition, the in vitro study indicated that incubation of the lysosomal fraction from kidneys of normal rats with TOB (30 micrograms/ml) significantly increased the NAG release, compared with that of the non-treated lysosomal fraction. However, the preincubated mixture of TOB (30 micrograms/ml) and LMOX (50 micrograms/ml) in vitro significantly suppressed the release of NAG from lysosomes by 85%. These results suggest that the suppression of the releases of NAG from lysosomes by the combination of TOB with LMOX may contribute to the protective effect of LMOX against TOB nephrotoxicity.
研究了单独使用妥布霉素(TOB)以及与拉氧头孢(LMOX)联合使用对大鼠肾溶酶体膜稳定性的影响。大鼠分别接受以下处理:单独注射TOB(90毫克/千克/天,皮下注射);单独注射LMOX(2000毫克/千克/天,皮下注射);或同时注射TOB(90毫克/千克/天,皮下注射)和LMOX(2000毫克/千克/天,皮下注射),连续5天。在第1、3和5天分离大鼠肾溶酶体,并在含1毫摩尔乙二胺四乙酸(pH 7.0)的0.25摩尔/升蔗糖溶液中于37℃孵育20分钟。孵育后,测量从溶酶体释放的N - 乙酰 - β - D - 氨基葡萄糖苷酶(NAG)的活性,并计算NAG释放百分比作为溶酶体膜稳定性的指标。单独接受TOB治疗的大鼠溶酶体中NAG的释放百分比在第1天和第3天分别比正常大鼠高40%和50%。另一方面,TOB与LMOX联合治疗使单独使用TOB时溶酶体的NAG释放减少了约80%至100%。单独接受LMOX治疗的大鼠在第3天和第5天NAG释放百分比有不显著的轻微增加。此外,体外研究表明,与未处理的溶酶体部分相比,用TOB(30微克/毫升)孵育正常大鼠肾溶酶体部分可显著增加NAG释放。然而,TOB(30微克/毫升)和LMOX(50微克/毫升)的体外预孵育混合物可显著抑制溶酶体NAG释放达85%。这些结果表明,TOB与LMOX联合抑制溶酶体中NAG的释放可能有助于LMOX对TOB肾毒性的保护作用。